Aaron Wealth Advisors LLC Purchases 245 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Aaron Wealth Advisors LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,186 shares of the pharmaceutical company’s stock after purchasing an additional 245 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,482,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Brookstone Capital Management boosted its holdings in Vertex Pharmaceuticals by 11.1% in the first quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock worth $990,000 after acquiring an additional 237 shares in the last quarter. Creative Planning boosted its holdings in Vertex Pharmaceuticals by 5.3% in the second quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after acquiring an additional 3,998 shares in the last quarter. Blue Trust Inc. boosted its holdings in Vertex Pharmaceuticals by 640.0% in the second quarter. Blue Trust Inc. now owns 1,443 shares of the pharmaceutical company’s stock worth $676,000 after acquiring an additional 1,248 shares in the last quarter. Manning & Napier Advisors LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth $74,213,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth $21,008,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX traded down $15.00 during midday trading on Friday, reaching $483.73. The company had a trading volume of 449,463 shares, compared to its average volume of 1,168,875. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $474.92 and a two-hundred day moving average of $459.08. The company has a market cap of $124.83 billion, a P/E ratio of 31.34 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.53 EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the transaction, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,487 shares of company stock worth $14,657,149 over the last quarter. 0.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on VRTX. Guggenheim boosted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 1st. HC Wainwright boosted their price target on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Royal Bank of Canada decreased their price target on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Finally, JPMorgan Chase & Co. boosted their price target on Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $492.92.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.